Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer by Fritzsche, Florian R. et al.
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Class I histone deacetylases 1, 2 and 3 are highly expressed in renal 
cell cancer
Florian R Fritzsche†1,6, Wilko Weichert†1, Annika Röske1, Volker Gekeler3, 
Thomas Beckers4, Carsten Stephan2, Klaus Jung2,5, Katharina Scholman1, 
Carsten Denkert1, Manfred Dietel1 and Glen Kristiansen*1,6
Address: 1Institute of Pathology, Charité – Universitätsmedizin, Berlin, Germany, 2Department of Urology, Charité – Universitätsmedizin, Berlin, 
Germany, 3Nycomed GmbH, Konstanz, Germany, 4Oncotest GmbH, Freiburg, Germany, 5Berlin Institute for Urologic Research, Berlin, Germany 
and 6Institute of Surgical Pathology, UniversitätsSpital Zürich, Zurich, Switzerland
Email: Florian R Fritzsche - florian.fritzsche@usz.ch; Wilko Weichert - wilko.weichert@charite.de; Annika Röske - annika.roeske@charite.de; 
Volker Gekeler - volker.gekeler@web.de; Thomas Beckers - t.beckers@vff.uni-frankfurt.de; Carsten Stephan - carsten.stephan@charite.de; 
Klaus Jung - klaus.jung@charite.de; Katharina Scholman - katharinascholman@hotmail.com; Carsten Denkert - carsten.denkert@charite.de; 
Manfred Dietel - manfred.dietel@charite.de; Glen Kristiansen* - glen.kristiansen@usz.ch
* Corresponding author    †Equal contributors
Abstract
Background:  Enhanced activity of histone deacetylases (HDAC) is associated with more
aggressive tumour behaviour and tumour progression in various solid tumours. The over-
expression of these proteins and their known functions in malignant neoplasms has led to the
development of HDAC inhibitors (HDI) as new anti-neoplastic drugs. However, little is known
about HDAC expression in renal cell cancer.
Methods: We investigated the expression of HDAC 1, 2 and 3 in 106 renal cell carcinomas and
corresponding normal renal tissue by immunohistochemistry on tissue micro arrays and correlated
expression data with clinico-pathological parameters including patient survival.
Results: Almost 60% of renal cell carcinomas expressed the HDAC isoforms 1 and 2. In contrast,
HDAC 3 was only detected in 13% of all renal tumours, with particular low expression rates in the
clear cell subtype. HDAC 3 was significantly higher expressed in pT1/2 tumours in comparison to
pT3/4 tumours. Expression of class I HDAC isoforms correlated with each other and with the
proliferative activity of the tumours. We found no prognostic value of the expression of any of the
HDAC isoforms in this tumour entity.
Conclusion: Class I HDAC isoforms 1 and 2 are highly expressed in renal cell cancer, while
HDAC 3 shows low, histology dependent expression rates. These unexpected differences in the
expression patterns suggests alternative regulatory mechanisms of class I HDACs in renal cell
cancer and should be taken into account when trials with isoform selective HDI are being planned.
Whether HDAC expression in renal cancers is predictive of responsiveness for HDI will have to
be tested in further studies.
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Background
The family of histone deacetylases (HDAC) comprises 18
isoforms which are categorized into four classes. Func-
tionally, HDACs have been demonstrated to be involved
in the deacetylation of histone tails in the nucleosomal
organization units which leads to a tighter wrapping of
the DNA around the histone core, which in turn results in
an activation or inhibition of gene transcription [1]. In
addition, HDACs influence the direct acetylation pattern
of a variety of tumour relevant non-histone proteins, thus
influencing their subcellular localization, interaction part-
ners and functions [2,3]. Expression patterns of HDACs in
solid human tumours have been in the focus of our group
and many oncological researchers alike [4-9]. This
research has been mainly triggered and promoted by the
development of potent HDAC inhibitors (HDI) that have
already advanced to late phase clinical trials for a broad
variety of malignant human neoplasms [10,11]. An exam-
ple is vorinostat, an unselective HDI, that has recently
been approved for therapy of cutaneous T-cell lymphoma
by the Food and Drug Administration [12]. HDI inhibit
the enzymatic function of HDACs and thus change the
epigenetic configuration of the tumour cells genome
which influences the functions of many proteins [13,14].
Two of the most famous and best studied representatives
of this group of chemotherapeutics are valproic acid
(VPA) and suberoylanilide hydroxamic acid (SAHA, vori-
nostat). Both inhibit the function of class I and class II
HDACs which has experimentally been proven to cause
growth arrest, differentiation and/or apoptosis of cancer
cells in vitro and in vivo [15-20]. Furthermore, HDI sensi-
tize tumour cells for radiation induced apoptosis [21].
Surprisingly, the specific role of the different HDAC iso-
forms in carcinogenesis and tumour progression of renal
cell cancer is not well understood.
Renal cell carcinoma (RCC) is one of the most lethal gen-
ito-urinary malignancies with about 13.000 estimated
cancer related deaths in the USA in 2008 [22]. Current
therapies for renal cell cancer include total nephrectomy
or partial nephron-sparing surgery and chemotherapeu-
tics like interferons or interleukins. Recently in vitro stud-
ies and animal experiments have shown a potential use of
HDI in this tumour entity [18-20]. In this study, we ana-
lyzed expression of the class I HDAC isoforms 1–3 in a
clinically well characterized patient cohort of RCC to clar-
ify the diagnostic and/or prognostic value of these
enzymes.
Methods
Patient characteristics
One-hundred-six patients diagnosed for renal cancer at
the Institute of Pathology, Charité – Universitätsmedizin
Berlin between 2003 and 2005 were enclosed in this
study. The Charité University Ethics Committee has
approved the study under the title 'Retrospektive Untersu-
chung von Gewebeproben mittels immunhistoche-
mischer Färbung und molekularbiologischer Methoden'
('Retrospective analysis of tissue samples by immunohis-
tochemistry and molecular biological techniques') (EA1/
06/2004) on 20 September 2004. Patient age ranged
between 28 and 92 years with a median of 62. Histologi-
cal diagnosis was established according to the guidelines
of the World Health Organization [23]. Cases were
selected according to tissue availability and were not strat-
ified for any known preoperative or prognostic factor. 84
(79.3%) patients had clear cell RCC (ccRCC), 17 (16.0%)
papillary RCC and 5 (4.7%) chromophobe RCC. Twenty-
three patients had systemic disease (M1, evaluated by pre-
operative CT-scan) at the time of diagnosis. Clinical fol-
low-up data, as annually assessed survival time was
available for all patients. The median follow-up time of all
cases was 30 months, ranging from one to 47 months.
Twenty-two (20.8%) patients died from renal cancer dur-
ing follow up. The pT status was as follows: pT1 – 53
(50.0%), pT2 – 3 (2.8%), pT3 – 47 (44.3%) and pT4 – 3
(2.8%). Twelve patients (11.3%) had pathologically con-
firmed nodal metastases. Fifty (47.2%) patients had no
nodal metastases (pN0). In 44 (41.5%) patients lymph
nodes were not examined (pNx). Tumour grades, accord-
ing to Fuhrman, were G1 – 11 (10.4%), G2 – 74 (69.8%),
G3 – 17 (16.0%) and G4 – 4 (3.8%) respectively (Table
1).
Tissue Micro Array construction
A tissue micro array (TMA) was constructed as previously
described [24]. Suitable areas for tissue retrieval were
marked on hematoxylin/eosin sections, punched out of
the paraffin block and inserted into a recipient block. A
tissue arrayer (Beecher Instruments, Woodland, USA)
with a core diameter of 0.6 mm was used. The RCC TMA
was constructed to represent 108 cases with two spots
from the tumour and two spots representing matching
normal tissue from the cortex region of the kidney. In four
cases, the "normal" spots did not represent kidney tissue,
leaving 104 cases with matched tumour and normal tis-
sue, plus four cases with tumour only. The whole TMA
was accomplished on three paraffin blocks. Tissue spots of
two tumours were lost during processing.
Immunohistochemistry
The TMA was freshly cut (3 μm). For immunohistochem-
ical detection of HDAC isoforms on tissue samples, predi-
luted polyclonal rabbit IgG antibody directed against
HDAC1 (1:11, Abcam, Cambridge, UK), monoclonal
mouse IgG antibody directed against HDAC2 (1:5000,
Abcam) and monoclonal mouse IgG antibody directed
against HDAC3 (1:500, Becton Dickinson, Franklin Lakes,
NJ, USA) was used on 3 μm paraffin sections. For antigen
retrieval, deparaffinized slides were placed in 0.01 MBMC Cancer 2008, 8:381 http://www.biomedcentral.com/1471-2407/8/381
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sodium citrate buffer, pH 6.0 and boiled for 5 minutes in
a pressure cooker. After several rinses in TBS and pre-treat-
ment with blocking reagent (Dako, Glostrup, Denmark)
for 5 minutes, slides were incubated with primary anti-
body in antibody diluent solution (Zymed, San Francisco,
CA, USA) for 20 minutes at room temperature and subse-
quently at 4°C overnight. After washing the slides in TBS,
bound antibody was detected by applying a streptavidin-
biotin system (BioGenex, San Ramon, CA, USA) due to a
standard protocol with standard antibody dilutions as
supplied by the manufacturers. For color development, a
fast red system (Sigma, Deisenhofen, Germany) was used.
The slides were cover slipped using Aquatex (Merck, Gern-
sheim, Germany).
Evaluation of staining of tissue slides
Nuclear staining of HDAC isoforms was scored by apply-
ing a semiquantitative immunoreactivity scoring (IRS)
system that incorporates the percentual area and the
intensity of immunoreactivity resulting in a score ranging
Table 1: Expression of class I HDAC isoforms in renal cell carcinoma stratified for selected tumour parameters
Total HDAC1 
low
HDAC1 
high
p-value HDAC2 
low
HDAC2 
high
p-value HDAC3 
low
HDAC3 
high
p-value
All Cases 106
(100%)
47
(44.3%)
59
(55.7%)
46
(43.4%)
60
(56.6%)
92
(86.8%)
14
(13.2%)
Age ≤ 61 49
(46.2%)
23
(46.9%)
26
(53.1%)
0.696+ 19
(38.8%)
30 (61.2%) 0.434+ 42
(85.7%)
7
(14.3%)
0.781+
Age >61 57
(53.8%)
24
(42.1%)
33
(57.9%)
27
(47.4%)
30 (52.6%) 50
(87.7%)
7
(12.3%)
pT1 53
(50.0%)
20
(37.7%)
33
(62.3%)
0.088* 19
(35.8%)
34
(64.2)
0.088* 43
(81.1%)
10
(18.9)
0.052*
pT2 3
(2.8%)
0
(0.0%)
3
(100.0%)
0
(0.0%)
3
(100.0%)
2
(66.7%)
1
(33.3%)
pT3 47
(44.4%)
25
(53.2%)
22
(46.8%)
26
(55.3%)
21 (44.7%) 44
(93.6%)
3
(6.4%)
pT4 3
(2.8%)
2
(66.7%)
1
(33.3%)
1
(33.3%)
2
(66.7%)
3
(100.0%)
0
(0.0%)
Grading 
G1
11
(10.4%)
6
(54.5%)
5
(45.5%)
0.596* 1
(9.1%)
10 (90.9%) 0.207* 10
(90.9%)
1
(9.1%)
0.602*
Grading 
G2
74
(69.8%)
33
(44.6%)
41
(55.4%)
42
(56.8%)
32 (43.2%) 64
(86.5%)
10
(13.5%)
Grading 
G3
17
(16.0%)
6
(35.3%)
11
(64.7%)
3
(17.6%)
14
(82.4%)
15
(88.2%)
2
(11.8%)
Grading 
G4
4
(3.8%)
2
(50.0%)
2
(50.0%)
0
(0.0%)
4
(100.0%)
3
(75.0%)
1
(25.0%)
pN0# 50
(47.2%)
27
(54.0%)
23
(46.0%)
0.335+ 26
(52.0%)
24
(48.0%)
0.339+ 44
(88.0%)
6
(12.0%)
1.000+
pN1/2 12
(11.3%)
4
(33.3%)
8
(66.7%)
4
(33.3%)
8
(66.7%)
11
(91.7%)
1
(8.3%)
M0 83
(78.3%)
37
(44.6%)
24
(55.4%)
0.559+ 37
(44.6%)
46
(55.4%)
0.412+ 72
(86.7%)
11
(13.3%)
.642+
M1 23
(21.7%)
10
(43.5%)
13
(56.5%)
9
(39.1%)
14
(60.9)
20
(87.0%)
3
(13.0%)
HDAC1 
low
47
(44.3%)
- - - 31 (66.0%) 16
(34.0%)
<0.001+ 43
(91.5%)
4
(8.5%)
0.255+
HDAC1 
high
59
(55.7%)
-- 1 5
(25.4%)
44 (74.6%) 49
(83.1%)
10
(16.9%)
HDAC2 
low
46
(43.4%)
31
(67.4%)
15
(32.6%)
<0.001+ --- 4 5
(97.8%)
1
(2.2%)
0.003+
HDAC2 
high
60
(56.6%)
16
(26.7%)
44
(73.3%)
-- 4 7
(78.3%)
13
(21.7%)
HDAC3 
low
92
(86.8%)
43
(46.7%)
49
(53.3%)
0.255+ 45
(48.9%)
47
(51.1%)
0.003+ ---
HDAC3 
high
14 (13.2%) 4
(28.6%)
10
(71.4%)
1
(7.1%)
13 (92.9%) - -
Ki-67 index 
≤ 10%
70
(66.0%)
38
(54.3%)
32
(45.7%)
0.007+ 37
(52.9%)
33
(47.1%)
0.007+ 64
(91.4%)
6
(8.6%)
0.068+
Ki-67 index 
> 10%
36
(34.0%)
9
(25.0%)
27
(75.0%)
9
(25.0%)
27
(75.0%)
28
(77.8%)
8
(22.2%)
+ Fisher's exact test, * Chi-square test for trends, # 44 cases (41.5%) were pNxBMC Cancer 2008, 8:381 http://www.biomedcentral.com/1471-2407/8/381
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from 0 to 12, as described [25]. Two clinical pathologists
independently scored the cases. Differences in the evalua-
tion were discussed at a multiheaded microscope until
consensus was reached. For statistical analysis, cases
exhibiting an IRS from 0–6 were lumped in a HDAC low
group whereas cases with a higher IRS (7–12) were desig-
nated HDAC high. This cut-off was chosen to allow for a
better comparability with previous works [7-9]. Addi-
tional cut-off points (quartiles) were evaluated for each
HDAC.
Statistical analysis
Statistical analyses were performed with SPSS 15.0 (SPSS
Inc., Chicago, USA). Fisher's exact and chi-square tests
were applied to assess associations between expression of
HDACs and clinico-pathological parameters. Correlations
were computed using Spearman's bivariate rank order cor-
relation. Univariate survival analysis was carried out
according to Kaplan-Meier, differences in survival curves
were assessed with the log rank test. P-values < 0.05 were
considered significant.
Results
Expression of HDACs in renal cell cancer
Normal renal tissue showed moderate to strong expres-
sion of all three types of class I HDACs in some but not all
glomerular cells. Tubular epithelia were partially positive
and expression patterns differed clearly between specific
HDAC 1 expression in normal and malignant renal tissue Figure 1
HDAC 1 expression in normal and malignant renal tissue. In benign renal tissue HDAC 1 is focally expressed in nuclei 
of mesangial cells of the glomeruli and also tubular epithelia with a stronger expression in the distal part of the nephron (A). 
Clear cell RCC negative for HDAC 1, contrasting to the relatively strong staining in adjacent stroma (B). RCC displaying a 
strong and homogenous nuclear positivity in tumour cells (C). Papillary (D1) and chromophobe (D2) RCC with strong HDAC 
1 expression.
D1 D2
A
C
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tubular subunits (Figures 1, 2, 3). It was noted that in gen-
eral HDAC 3 was fainter and less frequently expressed
than HDAC 1 and 2.
In renal cell carcinomas moderate to strong nuclear
HDAC1, HDAC2 and HDAC3 immunoreactivity was
detected in 55.7%, 56.6% and 13.2% of cases, respec-
tively. Low or no expression of class I HDAC was seen in
44.3%, 43.4% and 86.8% for the three different isoforms
whereas 9.4%, 11.3% and 72.6% of cases were completely
negative (IRS 0) for the respective HDACs (Figure 1, Table
1). The low rate of positivity for HDAC 3 resulted in a low
rate of cases positive (IRS>6) for all three HDACs (9.4%,
n = 10), while the rate of cumulative HDAC low or nega-
tive cases (IRS ≤ 6) was 28.3% (n = 30). HDAC 1 and 2
were almost equally expressed in the different histological
subtypes of renal cell cancers. In contrast, HDAC 3 was
detected at high levels in only 7 (8.3%) out of 84 clear cell
but in 7 of 17 (41.2%) papillary carcinomas. All five
chromophobe carcinomas were negative for HDAC 3.
Interestingly, we recognized that even in HDAC negative
carcinomas some intra-tumoural stromal cells expressed
the class I HDACs.
Correlation of HDAC isoform expression with clinico-
pathological factors and survival
In bivariate correlation the HDAC IRS scores of all three
isoforms correlated significantly with each other and with
the Ki-67 (MIB-1) proliferation index (HDAC1: p = 0.009,
correlation coefficient (CC): 0.252; HDAC2: p < 0.001,
CC: 0.359; HDAC3: p = 0.015, CC: 0.235). Apart from a
HDAC 2 expression in normal and malignant renal tissue Figure 2
HDAC 2 expression in normal and malignant renal tissue. HDAC 2 was found to have a similar expression pattern as 
HDAC 1 with moderately positive normal glomerular and tubular cells (A). HDAC 2 negative clear cell carcinoma with dis-
tinctly positive stromal cells (B). Strong nuclear HDAC 2 expression in clear cell (C), papillary (D1) and chromophobe (D2) 
histologic subtypes of RCC.
A
D1 C
B
D2BMC Cancer 2008, 8:381 http://www.biomedcentral.com/1471-2407/8/381
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significant reciprocal correlation (Spearman rank order
correlation) of HDAC3 with pT status (p = 0.005, CC -
0.268) and a trend for HDAC2 in this direction (p =
0.061, CC -0.181) there were no other correlations with
age, grading, nodal status, or metastasis status.
In the χ-square tests (Table 1) the above mentioned corre-
lations could be partially confirmed in the grouped anal-
yses. Some p values remained just above the significance
level, most likely due to grouping effects.
Kaplan-Meyer survival analyses and log rank tests confirm
the conventional prognosticators pT status, nodal status,
distant metastasis and histopathological grading to be rel-
evant for overall patient survival in our cohort (Table 2).
HDAC expression did not reach significance in these anal-
yses, neither for a single isoform (Figure 4A–C) nor in a
combined analysis (not shown).
All analyses were also re-computed with alterative cut-off
levels, using the quartiles of the individual IRS for each
HDAC. None of these tests highlighted a significant prog-
nostic value for HDAC 1–3. Also, no correlations with
clinico-pathological parameters were found. Only for pT-
status there was a significant inverse association with
HDAC 3 if lumped according to the quartiles (p = 0.004–
0.006).
Discussion
In this study, HDAC class I isoforms were detected in nor-
mal renal tubular and glomerular tissues and to a variable
extent in renal cell cancers. The low expression rate of the
HDAC 3 expression in normal and malignant renal tissue Figure 3
HDAC 3 expression in normal and malignant renal tissue. HDAC 3 expression in normal renal tissue with positive 
glomerular and tubular epithelial cells (A). Partially sarcomatoid differentiated clear cell RCC with only very few rather weak 
to moderately positive tumour cells (B). Clear cell (C), papillary (D1) and chromophobe (D2) RCC with strong HDAC 3 
expression.
A
D2 D1 C
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HDAC3 isoform differs relevantly from that of the other
two isoforms, which are highly expressed in the majority
of renal tumours. These results are in contrast to the find-
ings in all malignant tumours analyzed so far, where
HDAC3 was the strongest and most frequently expressed
isoform of all three class I HDACs [4,7,8]. Especially the
absence of HDAC3 in the most common histological var-
iant of RCC (clear cell RCC) suggests different regulatory
mechanisms of the three isoforms in this tumour entity.
However, it is interesting that there is still a significant cor-
relation between the expression rates of all three HDACs.
The connection between HDAC expression and the prolif-
eration index (Ki-67) observed here in renal cell carcino-
mas has already been demonstrated for prostate cancer
and colorectal cancer [8,9]. This is further in line with
studies [18-20,26-28] showing that HDI treatment in vitro
and in vivo leads to an arrest in tumour cell proliferation.
We and others previously reported of associations of class
I HDACs with more aggressive tumours and even short-
ened patient survival in prostate cancer and gastric cancer
[7,8,29]. In our cohort we could not find relevant and sig-
nificant associations of the HDAC expression with
tumour grade and other clinico-pathological parameters.
This is somewhat surprising since HDACs are known to
have effects on tumour cell differentiation in vitro and in
vivo in other tumour entities [7-9,26,30]. However, the
missing correlation of HDAC expression with tumour
grade in RCC might be explained by the way tumour grade
is assessed in RCC. Fuhrman grade, which is recom-
Table 2: Patient survival in dependence of clinico-pathological parameters and HDAC isoform expression
Parameters No. of cases No. of events Two Year survival time (± SE) in months p-value
HDAC1 expression 0.285
low 47 12 76.6 (± 6.2)
high 59 10 83.1 (± 4.9)
HDAC2 expression 0.235
low 46 12 76.1 (± 6.3)
high 60 10 83.3 (± 4.8)
HDAC3 expression 0.906
low 92 19 80.5 (± 4.1)
high 14 3 78.6 (± 11.0)
Age 0.119
≤ 61 49 7 85.7 (± 5.0)
>61 57 15 75.4 (± 5.7)
pT stage <0.001
pT1 53 2 96.2 (± 2.6)
pT2 3 1 66.7 (± 27.2)
pT3 47 17 66.0 (± 6.9)
pT4 3 2 33.3 (± 27.2)
Histological grade <0.001
G1 11 0 -
G2 74 12 85.1 (± 4.1)
G3 17 7 58.8 (± 11.9)
G4 4 3 25.0 (± 21.7)
pN status 0.001
pN0 50 10 80.0 (± 5.7)
pN1/2 12 8 41.7 (± 14.2)
Metastasis <0.001
M0 47 5 89.4 (± 4.5)
M1 23 14 43.5 (± 10.3)
Ki-67 index 0.931
≤ 10% 70 15 80.0 (± 4.8)
>10% 36 7 80.6 (± 6.6)BMC Cancer 2008, 8:381 http://www.biomedcentral.com/1471-2407/8/381
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Kaplan-Meier survival curves for renal cell cancer patients according to class I HDAC expression patterns Figure 4
Kaplan-Meier survival curves for renal cell cancer patients according to class I HDAC expression patterns. For 
none of the HDAC isoforms 1–3 (A-C) a significant prognostic value for the patient survival times could be demonstrated.
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mended by the World Health Organization, evaluates
only nuclear morphology, whereas architectural features
of tumour differentiation are not considered. Therefore,
Fuhrman grade might be inappropriate to assess the rela-
tionship of HDAC expression to tumour differentiation,
which is the predominant basis for grading schemes of
other tumour entities. This might be at least a possible
explanation for the missing correlations of tumor grade
with HDAC expression.
Another rather unexpected finding was the reciprocal cor-
relation of HDAC3 with tumour stage (pT-status). Given
the overall low positivity for HDAC3, smaller distribution
irregularities might have relevant impact on the results. In
fact the papillary RCC, which were positive for HDAC3,
tended to be of lower tumour stage in our cohort. If the
papillary RCCs were omitted the significance of this corre-
lation was lost.
Although high rates of HDAC expression have been found
to be prognostic markers in other tumour entities, in RCC
no prognostic value could be demonstrated. A shortcom-
ing of the current study is that the acetylation status of the
histones in RCC has not been assessed. Toh et al. have
demonstrated that hyperacetylation of histones in
esophageal cancer is associated with HDAC 1 overexpres-
sion which suggests that HDAC expression might be a
marker of such an imbalance between acetylation and
deacetylation in the neoplasm [31]. This interesting point
should be focus of further study in RCC as well.
The expression of the class I HDACs in RCC might still
prove useful for individual decisions whether a patient
will profit from treatment with HDI, although until now
it is not clear whether HDAC protein expression as
assessed by immunohistochemistry is a predictor of treat-
ment response with HDI. Clearly, additional studies are
needed to clarify this point.
Conclusion
In conclusion, we demonstrated that the class I HDAC iso-
forms 1 and 2 are highly expressed in the majority of renal
cell cancers whereas HDAC 3 expression, in contrast to the
findings in other tumour entities, could only rarely be
detected, especially in clear cell RCC. Although HDAC
expression in RCC was not correlated with patient survival
times the expression patterns of HDACs could hypotheti-
cally be important to predict the response of RCC patients
to chemotherapies comprising one of the up-coming
HDAC inhibitor drugs. This should be focus of further
analyses.
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